[go: up one dir, main page]

WO2004091508A3 - Fullerene compositions for ameliorating dermatological conditions - Google Patents

Fullerene compositions for ameliorating dermatological conditions Download PDF

Info

Publication number
WO2004091508A3
WO2004091508A3 PCT/US2004/011155 US2004011155W WO2004091508A3 WO 2004091508 A3 WO2004091508 A3 WO 2004091508A3 US 2004011155 W US2004011155 W US 2004011155W WO 2004091508 A3 WO2004091508 A3 WO 2004091508A3
Authority
WO
WIPO (PCT)
Prior art keywords
core
fullerence
fullerene
dermatological conditions
ameliorating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/011155
Other languages
French (fr)
Other versions
WO2004091508A2 (en
Inventor
Stephen R Wilson
Yi-Zhen Hu
Tong Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
C Sixty Inc
Original Assignee
C Sixty Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C Sixty Inc filed Critical C Sixty Inc
Priority to CA002521818A priority Critical patent/CA2521818A1/en
Priority to JP2006509910A priority patent/JP2006524245A/en
Priority to EP04749994A priority patent/EP1615609A2/en
Priority to AU2004229497A priority patent/AU2004229497A1/en
Publication of WO2004091508A2 publication Critical patent/WO2004091508A2/en
Anticipated expiration legal-status Critical
Publication of WO2004091508A3 publication Critical patent/WO2004091508A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

This patent discloses a method of ameliorating a dermatological condition in the skin of a mammal, comprising administering a composition comprising a substituted fullerene to at least a portion of the skin of the mammal afflicted with the dermatological condition or potentially afflicted with the dermatological condition wherein the substituted fullerene comprises a fullerene core (Cn) and at least one of: (i) from 1 to 3 (>CX1X2) groups bonded to the fullerence core; (ii) from 1 to 18-X3 groups bonded to the fullerence core; (iii) from 1 to 6 -X4- groups bonded to the fullerence core; or (iv) from 1 to 6 dendrons bonded to the fullerence core.
PCT/US2004/011155 2003-04-10 2004-04-12 Fullerene compositions for ameliorating dermatological conditions Ceased WO2004091508A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002521818A CA2521818A1 (en) 2003-04-10 2004-04-12 Fullerene compositions for ameliorating dermatological conditions
JP2006509910A JP2006524245A (en) 2003-04-10 2004-04-12 Fullerene composition for improving dermatological symptoms
EP04749994A EP1615609A2 (en) 2003-04-10 2004-04-12 Fullerene compositions for ameliorating dermatological conditions
AU2004229497A AU2004229497A1 (en) 2003-04-10 2004-04-12 Fullerene compositions for ameliorating dermatological conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46191403P 2003-04-10 2003-04-10
US60/461,914 2003-04-10

Publications (2)

Publication Number Publication Date
WO2004091508A2 WO2004091508A2 (en) 2004-10-28
WO2004091508A3 true WO2004091508A3 (en) 2007-01-11

Family

ID=33299878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/011155 Ceased WO2004091508A2 (en) 2003-04-10 2004-04-12 Fullerene compositions for ameliorating dermatological conditions

Country Status (5)

Country Link
EP (1) EP1615609A2 (en)
JP (1) JP2006524245A (en)
AU (1) AU2004229497A1 (en)
CA (1) CA2521818A1 (en)
WO (1) WO2004091508A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070827A2 (en) * 2004-01-14 2005-08-04 William Marsh Rice University Fullerene based amino acids
JP2006160664A (en) * 2004-12-07 2006-06-22 Vitamin C60 Bioresearch Kk Composition for prevention and treatment of free radical disease
CN104069129A (en) * 2014-06-24 2014-10-01 苏州大德碳纳米科技有限公司 Externally-applied liquid for treating psoriasis and dermatitis as well as preparation method and application thereof
CN114306140A (en) * 2021-12-30 2022-04-12 赤峰福纳康生物技术有限公司 Fullerene lanolin and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912257A (en) * 1995-09-06 1999-06-15 The Research Foundation Of State University Of New York Two-photon upconverting dyes and applications
US6287765B1 (en) * 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
US6506928B1 (en) * 1998-02-25 2003-01-14 Siemens Axiva Gmbh & Co. Kg Dendrimeric fullerene derivatives, process for their preparation, and use as neuroprotectants

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648523A (en) * 1995-10-26 1997-07-15 Chiang Long Y Fullerene derivatives as free-radical scavengers
JP2000514412A (en) * 1996-06-03 2000-10-31 エフ・ホフマン―ラ ロシュ アーゲー Use of buckminsterfullerene for the treatment of neurotoxic damage
US6538153B1 (en) * 2001-09-25 2003-03-25 C Sixty Inc. Method of synthesis of water soluble fullerene polyacids using a macrocyclic malonate reactant

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912257A (en) * 1995-09-06 1999-06-15 The Research Foundation Of State University Of New York Two-photon upconverting dyes and applications
US6506928B1 (en) * 1998-02-25 2003-01-14 Siemens Axiva Gmbh & Co. Kg Dendrimeric fullerene derivatives, process for their preparation, and use as neuroprotectants
US6287765B1 (en) * 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules

Also Published As

Publication number Publication date
JP2006524245A (en) 2006-10-26
EP1615609A2 (en) 2006-01-18
WO2004091508A2 (en) 2004-10-28
CA2521818A1 (en) 2004-10-28
AU2004229497A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
WO2005035441A3 (en) Subtituted fullerene compositions and their use as antioxydants
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
CA2311356A1 (en) Method for treating alzheimer's disease
IL198783A0 (en) Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
HK1047693A1 (en) Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof
AU2001269688A1 (en) Combination containing an antifolate and methylmalonic acid lowering agent
WO2004091502A3 (en) 1,2,4-oxadiazole benzoic acid compounds
WO2001085203A3 (en) Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
WO2001068138A3 (en) Intradermal-penetration agents for topical local anesthetic administration
AU2002305346A1 (en) Techniques and compositions for treating cardiovascular disease by (in vivo) gene delivery
EP2298301A3 (en) Medicaments for increasing endogenous Erythropoietin (EPO)
AU2002311886A1 (en) Process for preparing purified shilajit composition from native shilajit
WO2000074662A3 (en) Arthritis treatment
WO2004015085A3 (en) Method and compositions relating to 5’-chimeric ribonucleic acids
WO2004083369A3 (en) Tissue binding composition
CA2367387A1 (en) Composition comprising isoquercetin and ascorbic acid in a sustained release form
CA2348836A1 (en) Feed for livestock
WO2005079396A3 (en) O,o'-amidomalonate and n,o-amidomalonate platinum complexes
WO2006004695A3 (en) Cosmetic compositions and methods comprising rhodiola rosea
WO2004091508A3 (en) Fullerene compositions for ameliorating dermatological conditions
EP1621207A3 (en) Mixture of defibrotide and G-CSF, and its use for activating haematopoietic progenitors
WO2003049667A3 (en) The method of treating cancer
CA2417837A1 (en) Compositions for ameliorating attention-deficient/hyperactivity disorder
WO2002060533A3 (en) Pharmaceutical compositions containing beta-mimetic agents and having few side-effects

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2521818

Country of ref document: CA

Ref document number: 2006509910

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004229497

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004749994

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004229497

Country of ref document: AU

Date of ref document: 20040412

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004229497

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004749994

Country of ref document: EP